Pantherna Therapeutics is open for diverse types of collaborations with pharmaceutical and biotech companies.

Pantherna plans to partner its in-house development programs at the pre-clinical or clinical stage.

We focus on patients with an Acute Respiratory Distress Syndrome (ARDS), a life-threatening condition associated with viral and bacterial lung infections.

In addition, we are interested in research collaborations and pre-clinical development agreements with industry partners to extend the applications of Pantherna‚Äôs proprietary lipid nanoparticle mRNA expression technology platforms (PTX_LNP™, PTXmRNA™).

We are open to research agreements with academia and biotech that have complementary research interest and corresponding capabilities in selected indications proposed by the respective partner.

Active collaborations

Business development contact

Klaus Giese


Ansgar Santel